ERTUGLIFLOZIN (Steglatro®)

Clinical Indication

Type 2 diabetes mellitus (for 18 years and over) as monotherapy or with metformin or with metformin and a dipeptidyl peptidase-4 inhibitor

Comments

In line with NICE TA 572 and NICE TA 583

Date of classification

June 2019

Yellow

Medicines initiated or recommended by a specialist service for prescribing in primary care which do not require initiation or ongoing oversight by the specialist. There are no specific paperwork requirements between provider organisations and a verbal request may be acceptable through advice and guidance as long enough information is provided so that the transfer of care is safe.